MTOR and neoplasm: While PFS rates were higher in combination regimens that included another targeted agent (mTOR_T, mTOR_CT), the OS rates were similar across all therapy regimen subtypes indicating that mTOR inhibitors in combination regimens offer OS benefits while tandem targeting of additional tumor pathways yields PFS benefits as well apart from to OS benefits.